MetaVia Reports Positive Phase 1b Clinical Trial Results for Obesity Drug DA-1726
MTVA sits 54% above its 52-week low of $6.05 on light trading volume (0.1× avg).
Summary
MetaVia Inc. announced positive, statistically significant Phase 1b clinical trial results for its obesity drug DA-1726, showing robust weight loss, improved glucose control, and a favorable safety profile.
Key Events · Product Development and Regulatory · MTVA
-
Positive Phase 1b Trial Results
MetaVia announced statistically significant positive results from the 8-week, non-titrated 48 mg cohort of its Phase 1b clinical trial for DA-1726, a novel dual GLP1R/GCGR agonist for the treatment of obesity.
-
Robust Weight Loss and Metabolic Improvements
Patients achieved an average 9.1% weight reduction (21.2 lbs) and a statistically significant 9.8 cm reduction in waist circumference by Day 54. Fasted glucose improved by 12.3 mg/dL, and liver stiffness (VCTE) reduced by 23.7%.
-
Favorable Safety Profile
The trial reported no treatment-related discontinuations, with gastrointestinal events being mild to moderate in severity, indicating good tolerability for DA-1726.
-
Differentiated Potential Highlighted
CEO Hyung Heon Kim emphasized the drug's potential as a 'best-in-class treatment option' due to its compelling balance of weight loss, metabolic improvement, direct hepatic benefit, and tolerability.
Analysis · MTVA · Life Sciences
MetaVia Inc., a clinical-stage biotechnology company, announced highly encouraging Phase 1b clinical trial results for its obesity drug candidate, DA-1726. The data demonstrated statistically significant weight loss, improved glucose control, and notable reductions in liver stiffness, alongside a favorable safety profile. These positive outcomes for a dual GLP1R/GCGR agonist in a competitive market are a significant de-risking event for the company and could substantially enhance its valuation and future development prospects.
At the time of this filing, MTVA was trading at $9.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22M. The 52-week trading range was $6.05 to $30.25. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.